Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review
| Autor: | Takanari Kitazono, Tetsuro Ago, Noriko Makihara, Hitonori Takaba, Takao Morita, Kayo Wakisaka, Yuichiro Ohya |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Antibodies Monoclonal Humanized Antithrombins Dabigatran 03 medical and health sciences 0302 clinical medicine Internal medicine Atrial Fibrillation medicine Humans Thrombolytic Therapy 030212 general & internal medicine Recombinant tissue plasminogen activator Stroke Cardioembolic stroke Stroke scale business.industry Rehabilitation Clinical course Atrial fibrillation Idarucizumab Middle Aged medicine.disease Intracranial Embolism Cardiology Surgery Neurology (clinical) Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 27(7) |
| ISSN: | 1532-8511 |
| Popis: | Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab. The thrombolytic therapy following the use of idarucizumab significantly improved the patient's neurological symptoms without hemorrhagic complications, although acute arterial occlusion of the right lower limb was found during the clinical course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect